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Summary 
Background 
Rifaximin- reduces the risk of recurrence of overt hepatic encephalopathy. However, there 
remain concerns regarding the financial cost of the drug. 
Aim 
To study the impact of treatment with rifaximin- on healthcare resource utilisation using 
data from seven United Kingdom liver treatment centres. 
Methods 
All seven centres agreed a standardised data set a priori. Data characterising clinical, 
demographic and emergency hospital admissions were collected for the time-periods three, 
six and 12 months before and following initiation of rifaximin-. Admission rates and 
hospital length of stay before and during therapy were compared, and costs of admissions 
and drug acquisition were estimated using published sources. 
Results 
Data were available from 326 patients. The mean number of hospital admissions decreased 
from 2.1 per person per year before rifaximin- to 1.6 during treatment (p=0.001). The 
mean hospital length of stay decreased from 13.5 days before, to 8.6 days during rifaximin-
 (p=0.017). This resulted in an overall reduction in mean annual bed occupancy from 24.4 
days per person before, to 11.5 days during treatment (p<0.001). This translated into a 
mean reduction in inpatient costs of £6,607 per patient per year. Taking into account drug 
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costs of £3,379 for one year’s treatment with rifaximin-, there was an estimated annual 
mean saving of £3,228 per patient. 
Conclusions 
Initiation of treatment with rifaximin- was associated with a marked reduction in the 
number of hospital admissions and hospital length of stay. These data suggest that 
treatment of patients with rifaximin- for hepatic encephalopathy was generally cost 
saving.  
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Introduction 
Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver disease which 
results from liver dysfunction and/or portosystemic shunting 1. It spans a spectrum from 
covert HE—detectable only on neuropsychiatric testing—to overt HE, where clinical features 
such as confusion, impaired motor function, or decreased conscious level are manifest 2. 
Overt HE is estimated to affect 30%—40% of patients with cirrhosis at some time during 
their disease natural history 3, and it is associated with severely impaired health related 
quality of life (HRQOL) 4. 
The pathophysiology of HE is not fully understood but it is thought that the accumulation of 
neurotoxins derived from bacteria in the gut, such as ammonia, play a part 5. For this 
reason, most treatments for HE target the removal of toxins within the gut, or modify gut 
microbiota. Non-absorbable disaccharides such as lactulose are recommended as the first 
line treatment for HE 6 but despite this, recurrence rates of overt HE are high and patient 
compliance can be poor.  
The minimally absorbed antibiotic (0.01%) rifaximin- has been shown to reduce the risk of 
recurrence of HE in a high quality randomised controlled trial (RCT), with a hazard ratio of 
0.42 compared to placebo 7. In addition, this trial also showed an improvement in patient 
HRQOL 8. Rifaximin has been recommended as second-line therapy as an “add-on” to 
lactulose after a second episode of overt HE in the recent joint European Association for the 
Study of the Liver and American Association for the Study of Liver Disease guidelines 6. 
However, concerns have been raised about the cost effectiveness of rifaximin 9. 
There is emerging evidence to suggest that HE is associated with considerable financial 
burden to healthcare systems, partly due to high hospital admission rates 10, 11. Although the 
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RCT of rifaximin showed a significant reduction in the rate of hospitalisation (hazard ratio 
0.50) 7, there are understandable concerns about the reproducibility of such results outside 
the tightly controlled conditions of a RCT 12. Real world data, i.e. data derived from routine 
clinical practice, have the advantage of being potentially more generalisable than some of 
the results from RCTs. 
In this study, we compiled real world data from seven UK liver centres of patients with 
cirrhosis treated with rifaximin- for HE. The primary aim was to compare the hospital 
resource utilisation for patients before and after initiation of treatment with rifaximin, 
remembering that cirrhosis is a progressive disease with HE carrying the highest mortality of 
all decompensation events 13.  
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Methods 
Data collection 
A standardised data collection pro-forma was agreed by all participating centres in advance. 
Adult patients commenced on rifaximin were identified from the records of the pharmacy 
department at each specialist hospital centre, and patients who were treated for secondary 
prevention of overt HE on a background of chronic liver disease were included. Patients with 
HE due to acute liver failure and patients who had an indication other than HE were 
excluded. Patient records were reviewed in 2014 and clinical and demographic data were 
recorded, along with the number and duration of emergency hospital admissions for the 
periods three, six and 12 months before and after exposure to rifaximin. Other relevant 
parameters which were collected included disease aetiology, abstinence status and length 
of abstinence in alcohol-related liver disease (ARLD), time since referral to a hepatologist or 
gastroenterologist, the presence of a transjugular intrahepatic portosystemic shunt (TIPSS), 
liver transplant status and mortality. In order to estimate disease severity, Model for End 
Stage Liver Disease (MELD) was calculated at baseline, at three months and at the end of 
follow-up. MELD is calculated from serum bilirubin, creatinine and the international 
normalised ratio (INR) and has been shown to accurately predict three month prognosis 
following transjugular intrahepatic portosystemic shunt (TIPSS) insertion 14. More recently 
MELD has been shown to predict outcome of patients listed for liver transplant and is used 
for the prioritisation of patients on the active liver transplant list  in the US 15 Inclusion of 
aetiology or complication adds little to the validity of the score 16. Unlike the Child Pugh 
score, MELD is independent of the presence and severity of HE 17 and was therefore chosen 
for use in this study. 
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Estimation of financial costs 
Table 2 shows the sources and values used to estimate costs. Inpatient costs were 
estimated in UK pounds at 2008/9 prices from published NHS sources at a mean cost of 
£513 per day for non-elective admissions with liver disease 18. Rifaximin drug costs were 
calculated from the price published in the British National Formulary of £259 for 56 550 mg 
tablets 19, giving an annual drug treatment cost of £3,379 for the licensed HE dose of 550mg 
twice daily.  
Statistical analysis 
Whilst admissions data were non-normally distributed, the arithmetic mean value was used 
to compare these values because we aimed to describe effects at the healthcare system 
level, rather than at the individual patient level. Mean admission rates and hospital length 
of stay (HLOS) before and during rifaximin exposure were compared using paired samples t-
tests. Otherwise, non-parametrically distributed data were compared using independent-
samples Mann Whitney U tests or related-samples Wilcoxon signed rank test. The 
relationship between disease severity and response to rifaximin were explored using 
Pearson’s correlation between baseline MELD score and HLOS. All statistical analyses were 
carried out using SPSS version 21. 
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Results 
Three hundred and twenty-six patients were identified across the seven centres. 169 
patients (51.8%) were prescribed rifaximin at a dose of 550mg twice daily, 151 (46.3%) were 
prescribed 400mg twice daily and six (1.8%) were taking another dose. The patient 
characteristics are summarised in Table 1. The most common liver disease aetiology was 
ARLD, affecting 199 patients (61%), 20 of whom also had another aetiology recorded (HCV, 
12 patients; HBV, two; non-alcoholic fatty liver disease (NAFLD), four; haemochromatosis, 
two patients). Non-alcoholic steatohepatitis (NASH) and infection with hepatitis C virus 
(HCV) accounted for 15% and 13% of patients, respectively. Ten patients had hepatocellular 
carcinoma. Mean age was 59 (S.D. 12) years and 225 (69%) were male. 282 patients (87%) 
were prescribed concurrent lactulose. In terms of disease severity, mean MELD score was 
15.1 (S.D. 5.8) and Child Pugh grades were as follows: A, 29 (9%); B: 141 (43%); and C, 124 
(38%). 33 patients (10%) had a TIPSS placed prior to the initiation of exposure to rifaximin, 
12 of which were placed within six months of rifaximin treatment initiation. 
Of the patients with ARLD, 115 (58%) were abstinent from alcohol when rifaximin was 
initiated, 64 (32%) were actively drinking alcohol, and in 22 (11%) the alcohol status was 
unclear. Of the patients who abstained from alcohol, 69 (60%) had been abstinent for more 
one year, 24 (21%) for six to 12 months, whilst 20 (17%) had been abstinent for less than six 
months. 
The time interval between referral to a liver specialist and commencement of rifaximin was 
less than three months in 37 patients (11%), three to six months in 24 (7%), six months to 
one year in 26 (8%) and more than one year in 169 patients (52%). Time since referral was 
unclear in 70 patients (21%). 
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The outcomes of all patients are illustrated in figure one.  69 patients (21%) died within one 
year of rifaximin treatment initiation. The 30 day, 90 and 180 day mortality rates were 6%, 
11% and 17%, respectively. Median baseline MELD score was higher in the patients who 
died (17.6, IQR 8.7) compared with those who remained alive and had not been 
transplanted at one year (12.6, IQR 5.6; p<0.001). There were 45 patients (14%) who 
underwent liver transplantation within one year of treatment initiation with rifaximin, with 
a median baseline MELD of 17.4 (IQR 6.4). Rifaximin was discontinued in 31 (10%) patients; 
in five this was because no improvement in clinical condition was observed, in 11 the liver 
function had improved substantially, or HE was felt to have resolved. Two patients reported 
adverse events (nausea in one and not recorded in the other) and five were non-compliant. 
There were no reported cases of Clostridium difficile infection. 
Of the remaining 181 patients, complete data covering all study periods (3, 6 and 12 months 
before and after rifaximin exposure) were available for 141 patients (78%). Figure 2 
illustrates the pattern of admissions and hospital length of stay (HLOS) over all periods, 
showing that admissions increased over the year prior to rifaximin with the greatest number 
and longest HLOS occurring during the three months prior to rifaximin initiation (mean 0.35 
admissions and 4.47 days per month). During rifaximin treatment, hospital admissions 
decreased, with a progressive reduction in the HLOS throughout the year from 2.14 days per 
month in the year prior, to 1.02 days per month (p<0.001) in the year following rifaximin 
treatment initiation. 
There were complete, paired, 12 monthly data before and after rifaximin exposure available 
for 158 (87%) of the patients who remained alive and had not undergone liver 
transplantation. This showed a significant reduction in the mean number of emergency 
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hospital admissions from 2.1 (SD 2.4) admissions before to 1.6 (SD 2.0) during rifaximin 
treatment (p=0.001). The mean HLOS per admission reduced from 13.5 (SD 15.9) days 
before to 8.6 (SD 11.5) days during rifaximin treatment (p=0.017). This amounted to an 
overall reduction in the mean annual HLOS from 24.4 (SD 29.7) days per year, to 11.5 (SD 
18.6) days per year following initiation of rifaximin (p<0.001). 
Estimated inpatient costs, using published NHS reference prices, showed that mean annual 
emergency inpatient admission costs were reduced from £12,522 per year prior to rifaximin 
initiation, to £5,915 per year following rifaximin treatment initiation, an annual saving of 
£6,607, without accounting for the drug acquisition cost. Including the drug cost of one 
year’s treatment with rifaximin (£3,379), resulted in a mean saving of £3,228 per patient per 
year (Figure 3). 
Comparing disease severity data from patients with a MELD score available at both baseline 
and at three months (70—110 days) after treatment initiation with rifaximin (n=118), there 
was no change from median MELD score at baseline (14.0, IQR 6.3) to three months (13.4, 
IQR 6.5, p=0.309). Similarly, in patients with MELD data at baseline and one year (274—456 
days; n=109) there was no significant change from median MELD at baseline (11.6, IQR 4.8) 
to one year (11.8, IQR 5.4; p=0.150).  
There was no correlation between baseline MELD and the reduction in emergency hospital 
admissions (Pearson correlation=0.025; p=0.747). There was no statistically significant 
difference in the change in HLOS comparing patients with previous TIPSS to those without 
(mean annual reduction in HLOS 13.3 (SD 29.3) days vs 9.6 (SD 11.5) days, p=0.305). No 
difference was observed between the median reduction in HLOS of patients under the care 
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of a liver specialist for less than three months and those treated for more than three 
months (12.0, IQR 42.8 days vs 7.0, IQR 22.0 days, p=0.491). 
Of patients with ARLD, those who were actively drinking alcohol at baseline had a more 
pronounced reduction in their median annual HLOS at 19.0 days (IQR 44.0) than did those 
who were abstinent, at 9.0 days (IQR 19.0) which was nearing significance at the 
conventional level of significance (p=0.052). However, the reduction in annual HLOS was 
similar between those patients who achieved abstinence and those who continued drinking 
during the one year follow up (20.0 days (IQR 36.0) vs 23.5 days (IQR 49.8; p=0.934). Given 
the potential impact of active alcohol consumption on the likelihood of being admitted to 
hospital, the 12 month data was analysed excluding the ARLD patients who were not 
abstinent at baseline. This showed a reduction in the mean admission number from 1.9 (SD 
1.9) to 1.4 (SD 2.3) days (p=0.003), and annual HLOS reduced from 19.9 (SD 26.4) days 
before rifaximin to 9.6 (SD 16.7) days after (p<0.001). 
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Discussion 
This observational study characterised data from seven large, UK hospitals, representative 
of the spectrum of liver centres from district general hospitals, to tertiary and liver 
transplant units. We investigated the impact of treatment with rifaximin on hospital 
resource utilisation in patients with HE on a background of cirrhosis. We used a before and 
after design, effectively allowing patients to be used as their own controls with standardised 
datasets collected from the seven UK centres. We believed that for a progressive disease 
such as advanced liver disease that this would provide a conservative picture of any 
resulting change, given that we would expect there to be a natural increase in resource 
utilisation resulting from a progressive deterioration in clinical condition.  
There is good evidence for the efficacy of rifaximin as second-line treatment in HE, in 
particular in combination with lactulose 7. However, there remain reservations about the 
cost effectiveness of the drug and there has been a reluctance to approve its use in some 
countries 9. Given the high level of resource utilisation associated with HE and, in particular, 
high inpatient costs, we aimed to investigate the impact of rifaximin on this specific cost of 
care. Overall we found a 35% reduction in the mean number of annual emergency inpatient 
admissions (2.1 to 1.6 admissions), and a 53% reduction in mean annual bed occupancy 
(24.4 to 11.5 days) due to the combined impact on resource use of a reduction in hospital 
admissions, and a further saving from a reduction in hospital length of stay when patients 
were actually admitted. 
We considered a number of potential study limitations. One of these, alcohol consumption, 
was thought to potentially play an important role. Patients who were actively drinking 
alcohol at baseline had a more pronounced reduction in admissions following rifaximin 
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exposure. Interestingly, this effect was not confined to patients who subsequently became 
abstinent but was also evident in those patients who continued to drink alcohol during the 
period of follow-up. One explanation for this could be that, even in active drinkers, alcohol 
intake was considerably reduced during follow-up resulting in a degree of re-compensation 
of liver function and/or fewer alcohol-related admissions, such as alcohol withdrawal. 
Separate analysis of admissions data following exclusion of those with ARLD who continued 
drinking alcohol showed that the HLOS was reduced for these patients, both before (19.8 
days) and during rifaximin (9.6 days) but the overall percentage reduction in resource use 
remained similar at 52%. The length of time patients had been under the care of a liver 
specialist (gastroenterologist or hepatologist) was also examined to determine if patients 
who had been recently referred had other aspects of their care optimised, alongside the 
commencement of rifaximin. However, we found no difference comparing patients who had 
been under the care of a specialist for less than three months with those attending a 
specialist for a longer time period. Liver disease severity, as measured by MELD score, was 
also investigated. There was no change from baseline MELD to MELD at either three months 
or one year. In addition, there was no correlation observed between baseline MELD and 
HLOS, suggesting that disease severity alone was not associated with a treatment response 
to rifaximin. 
In terms of published data on this matter, to our knowledge there is one other study which 
considered the impact of rifaximin on healthcare resource utilisation but it had a number of 
limitations 20. All patients had been taking lactulose for six months or more for HE and were 
then switched to rifaximin when the drug became available in the United States. The cohort 
studied did not therefore accurately reflect what is now standard clinical practice where 
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rifaximin is reserved for patients with recurrent overt HE and where it will be prescribed in 
addition to, not instead of, lactulose. 
By contrast, our study included patients who were representative of current evidence-based 
practice. The majority (87%) of patients were prescribed concurrent lactulose, similar to the 
91% in the previous RCT 7, and standard practice across all seven centres was for rifaximin to 
be used as a second line therapy. Another strength of our study was the multicentre nature 
of the study that included seven specialist liver centres (two liver transplant centres, three 
tertiary liver centres and two large district general hospitals) meaning that the results 
should be generalisable across clinical practice elsewhere.  
Retrospective studies can suffer from incomplete data. While we had some missing values, 
particularly in situations where admission data could not be accurately collected because 
patients were admitted to other hospitals, data covering the 12 months before and during 
rifaximin was available for 87% of the patients, thus providing a large and reasonably 
complete dataset. One potential criticism of our study design could be that all emergency 
admissions were included, rather than only those relating to HE related admissions. We 
chose this approach because pilot work had demonstrated that patients admitted for other, 
ostensibly unrelated reasons (e.g. limb fracture) turned out to have HE as a likely 
contributing factor upon case-note review. There is also the possibility that rifaximin has 
additional beneficial effects beyond control of HE, for example in reduction of portal 
hypertension 21 or prevention of spontaneous bacterial peritonitis 22, therefore it was felt 
that inclusion of all emergency admissions was most appropriate. In addition, HE was not a 
diagnostic code within the ICD-10 classification (the coding system used in all NHS hospitals) 
meaning that HE related admissions were likely to be underestimated. By excluding elective 
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admissions, frequent events such as hospital admissions for uncomplicated, large volume 
paracentesis did not contribute. We recognised that some, non-HE related emergency 
admissions may have been included, but this was thought to be constant both before and 
during rifaximin exposure.  
In conclusion, this study that characterised real world data from seven UK specialist liver 
centres demonstrated that treatment with rifaximin to reduce the frequency of overt HE in 
those with advanced liver disease was associated with a large reduction in hospital 
admissions and a reduction in length of stay even when hospital admission was required. 
Before rifaximin treatment mean annual HLOS was high, consistent with previous reports of 
healthcare resource utilisation 11, 23, 24. Following initiation with rifaximin treatment, annual 
HLOS fell by more than 50% resulting in a mean saving of £6,607 per patient per year in 
hospital admission costs in our cohort. After accounting for drug acquisition costs there 
remained a substantial financial saving of approximately £3,000 per patient per year. 
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Table 1 | Baseline characteristics of included patients*.  
 
Royal Bolton 
Hospital 
Bristol Royal 
Infirmary 
Ninewells 
Hospital, 
Dundee 
The Royal 
Liverpool 
Hospital 
King’s 
College 
London 
Freeman 
Hospital, 
Newcastle 
Queen 
Alexandra 
Hospital, 
Portsmouth All centres 
Patients (n) 30 45 25 49 78 64 35 326 
Age (years) 60.5 (11.2) 59.8 (12.3) 57.7 (13.1) 55.3 (13.1) 56.9 (12.1) 61.4 (9.5) 58.3 (11.4) 58.5 (11.8) 
Males (n, %) 18 (60.0%) 31 (68.8%) 17 (68.0%) 38 (77.5%) 55 (70.5%) 46 (71.9%) 20 (57.1%) 225 (69.0%) 
TIPSS (n, %) 0 (0.0%) 4 (8.9%) 9 (36.0%) 1 (2.0%) 10 (12.8%) 6 (9.4%) 5 (14.3%) 35 (10.7%) 
Concurrent lactulose 30 (100.0%) 40 (88.9%) 25 (100.0%) 49 (100.0%) 55 (70.5%) 53 (82.8%) 29 (82.9%) 282 (86.5%) 
Aetiology*        
     ARLD 25 (83.3%) 29 (64.4%) 13 (52.0%) 29 (59.2%) 42 (53.8%) 39 (60.9%) 22 (62.9%) 199 (61.0%) 
    NASH 3 (10.0%) 7 (15.6%) 9 (36.0%) 5 (10.2%) 7 (9.0%) 12 (18.8%) 6 (17.1%) 49 (15.0%) 
    HBV 0 (0.0%) 1 (2.2%) 0 (0.0%) 1 (2.0%) 1 (1.3%) 1 (1.6%) 0 (0.0%) 4 (1.2%) 
    HCV 3 (10.0%) 4 (8.9%) 3 (12.0) 11 (22.4%) 10 (12.8%) 8 (12.5%) 4 (11.4%) 43 (13.2%) 
    AIH/PBC/PSC 0 (0.0%) 3 (6.7%) 1 (4.0%) 3 (6.1%) 10 (12.8%) 1 (1.6%) 4 (11.4%) 22 (6.7%) 
    Cryptogenic 0 (0.0%) 1 (2.2%) 0 (0.0%) 3 (6.1%) 4 (5.1%) 4 (6.3%) 0 (0.0%) 12 (3.7%) 
    Miscellaneous 0 (0.0%) 1 (2.2%) 2 (8.0%) 2 (4.1%) 9 (11.5%) 2 (3.1%) 1 (2.9%) 17 (5.2%) 
Baseline MELD: mean (SD) 17.5 (5.6) 14.3 (4.6) 15.3 (5.2) 12.8 (4.6) 16.6 (6.9) 12.9 (3.7) 17.9 (6.9) 15.1 (5.8) 
    ≤10 1 (3.3%) 10 (22.2%) 3 (12.0%) 13 (26.5%) 8 (10.3%) 10 (15.6%) 4 (11.4%) 49 (15.0%) 
    10-15 11 (36.7%) 18 (40.0%) 9 (36.0%) 21 (42.9%) 32 (41.0%) 36 (56.3%) 12 (34.3%) 139 (42.6%) 
    15-25 15 (50.0%) 15 (33.3%) 11 (44.0%) 15 (30.6%) 26 (33.3%) 17 (26.6%) 15 (42.9%) 114 (35.0%) 
    ≥25 3 (10.0%) 0 (0.0%) 1 (4.0%) 0 (0.0%) 11 (14.1%) 0 (0.0%) 4 (11.4%) 19 (5.8%) 
    Unknown 0 (0.0%) 2 (4.4%) 1 (4.0%) 0 (0.0%) 1 (1.3%) 1 (1.6%) 0 (0.0% 5 (1.5%)  
Baseline Child Pugh class        
     A TO 1 (2.2%) 2 (8.0%) 9 (18.4%) 5 (6.4%) 9 (14.1%) 3 (8.6%) 29 (8.9%) 
    B BE 16 (35.6%) 14 (56.0%) 24 (49.0%) 39 (50.0%) 37 (57.8%) 11 (31.4%) 141 (43.2%) 
    C ADDED 26 (57.8%) 9 (36.0%) 16 (32.7%) 34 (43.6%) 18 (28.1%) 21 (60.0%) 124 (38.0%) 
    Unknown  2 (4.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 32 (9.8%) 
*Some patients had more than one liver disease aetiology.
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Table 2 | Cost estimates: sources and values 
Cost Source Value 
Rifaximin drug cost British National Formulary 
August 2015 19 
56 x 550 mg tablets = 
£259.23 
1 year treatment of 550mg 
twice daily = £3,379.25 
Cost of emergency admission 
with liver disease 
NHS reference costs 2013 to 
2014 18 
Liver Failure Disorders 
without Interventions, with 
CC Score 0-4: Non-elective 
inpatients short-stay 
Unit cost £513/day  
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 Figure 1 | Outcomes at one-year post initiation of treatment with rifaximin-α. 
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Figure 2 | Pattern of mean number of admissions (A) and mean length of emergency 
hospital admissions (B) during study period 
A 
 
B 
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Figure 3 | Box plot showing annual emergency admission costs before and during rifaximin (A, admissions only; B, admissions and drug 
acquisition). 
A 
 
 
 
 
B 
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